Where immune thrombocytopenia treatment is heading
Immune thrombocytopenia · Updated Nov 14, 2026
Immune thrombocytopenia (ITP) is an autoimmune condition in which antibodies destroy platelets, causing bruising, bleeding and fatigue; roughly 3 in 100,000 adults are diagnosed each year in the US, and many children get a short-lived form. Steroids work at first but often wear off. Platelet-boosting pills and injections (thrombopoietin receptor agonists), rituximab and fostamatinib are used next. Newer drugs aim at the immune cells behind the disease: a BTK inhibitor was approved in 2025, and short-course antibodies against B cells and plasma cells are in phase 3.
- 138studies open or running
- 22phase 3 trials
- 687papers published this year
- 15NIH-funded projects
-
Now
Nov 2026
A BTK inhibitor pill approvedHappened 23% durable response
Rilzabrutinib gave durable responses in 23% of heavily treated patients vs 0% with placebo; FDA approved August 2025.
23%: durable platelet response, vs 0% with placebo.
A short antibody courseHappened 54% free of treatment failure
Four monthly doses of ianalumab kept 54% free of treatment failure at a year vs 30%.
54%: free of treatment failure at 12 months (9 mg), vs 30%.
Pills first for childrenHappened 65% sustained response
Eltrombopag beat standard first treatment in children (65% vs 35% sustained response).
65%: sustained platelet response, vs 35%.
-
6 months
by May 2027
Ianalumab at diagnosisLikely
Novartis' VAYHIT1 (226 people), adding ianalumab to first-line steroids, finishes October 2026.
Adding belimumab to rituximabPossible
RITUX-PLUS 2 (132 people) finishes November 2026.
-
12 months
by Nov 2027
Ianalumab filingPossible
Positive VAYHIT2 results could support an approval application for ianalumab.
FcRn blockers retestedLong shot 13.7% response (subcutaneous)
After the subcutaneous trial missed (13.7% vs 16.2%), argenx is testing intravenous efgartigimod in ADVANCE NEXT (due June 2028).
13.7%: sustained platelet response, vs 16.2% with placebo.
-
3 years
by late 2029
Targeting plasma cellsPossible 91% platelet response
Takeda's mezagitamab phase 3 (171 people) is due March 2028, after 91% responded at the top dose in phase 2.
91%: platelet response at 600 mg, vs 23% with placebo.
Another BTK inhibitorPossible
Lilly's pirtobrutinib trial (68 people) is due February 2028.
-
5 years
by late 2031
Treating early to prevent chronic ITPPossible
Amgen's ROMISTER adds romiplostim to steroids at diagnosis; due September 2029.
CAR T cells for refractory ITPLong shot
Off-the-shelf CAR T cells are in early testing for the hardest cases.
The research paths
B-cell and plasma-cell targeting
91% platelet responseDetails and 5 trialsHide
Short-course antibodies against B cells (ianalumab) and plasma cells (anti-CD38), plus CAR T cells.
WatchVAYHIT1; mezagitamab phase 3.
- Ianalumab with first-line steroids (VAYHIT1)Novartis · 226 people · fully enrolled Oct 2026
- Ianalumab with thrombopoietin agonistsNovartis · 164 people · enrolling Jan 2029
- Mezagitamab vs placeboTakeda · 171 people · enrolling Mar 2028
- Belimumab plus rituximab (RITUX-PLUS 2)Assistance Publique - Hôpitaux de Paris · 132 people · enrolling Nov 2026
- CTX112, an off-the-shelf CAR T cellCRISPR Therapeutics · 60 people · enrolling Dec 2033
BTK inhibitors
23% durable responseDetails and 2 trialsHide
Oral drugs that reduce platelet destruction.
WatchPirtobrutinib; LUNA 4.
Platelet boosters and antibody lowering
65% sustained response (children)Details and 2 trialsHide
Thrombopoietin agonists used earlier; FcRn blockers with mixed results.
WatchROMISTER; ADVANCE NEXT.
Borrowed from other conditions
From B-cell cancers
Rilzabrutinib and pirtobrutinib
Approved / Phase 2
BTK inhibitors, a class first developed for lymphoma and CLL.
From Multiple myeloma
Anti-CD38 antibodies
Phase 3
The same target as daratumumab, used to remove antibody-making plasma cells.
From Lupus
Belimumab
Phase 2/3
A BAFF blocker added to rituximab to prevent B cells returning.
Open to join now
-
Chronic ITP
Mezagitamab
Locations and eligibility → -
Chronic ITP
Intravenous efgartigimod
Locations and eligibility → -
ITP
Rilzabrutinib
Locations and eligibility → -
ITP
Pirtobrutinib
Locations and eligibility → -
Newly diagnosed ITP
Romiplostim plus steroids
Locations and eligibility →
See every recruiting ITP trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Subcutaneous efgartigimod misses goal
ADVANCE SC, Am J Hematol.
Ianalumab course delays treatment failure
VAYHIT2, NEJM.
Mezagitamab raises platelets in phase 2
NEJM.
Standard treatment today
- Newly diagnosedSteroids (prednisone or dexamethasone), with IVIG for bleeding or very low counts.
- Persistent or chronicThrombopoietin receptor agonists (eltrombopag, romiplostim, avatrombopag), rituximab, fostamatinib or rilzabrutinib.
- RefractoryCombinations, splenectomy, or clinical trials.
- ChildrenOften observation; steroids, IVIG or eltrombopag when needed.
How to read this page, and sourcesHow to read this page, and sources
- Low platelets have many causes; ITP is diagnosed after others are ruled out.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See ITP trials recruiting now →